Manager × security

SILVERBACK ASSET MANAGEMENT LLC BRIDGEBIO PHARMA INC holdings history

BRIDGEBIO PHARMA INC · CUSIP 10806XAD4 · CIK 1278960

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, SILVERBACK ASSET MANAGEMENT LLC reported 19.53M BRIDGEBIO PHARMA INC (principal), valued at $21.73M, or 2.75% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.75%
Principal
19.53M
19,532,000
Reported value
$21.73M
USD

Principal decreased 11.35%; reported value decreased 12.24%, and weight changed -2.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Principal · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.75%19,532,000SEC filing ↗Filed Aug 13, 2026
Q1 20264.88%22,032,000SEC filing ↗Filed May 21, 2026Amended
Q4 20254.54%26,950,000SEC filing ↗Filed Feb 17, 2026
Q3 20251.21%9,450,000SEC filing ↗Filed Nov 13, 2025
Q2 20251.87%13,000,000SEC filing ↗Filed Aug 13, 2025
Q1 20251.31%9,000,000SEC filing ↗Filed May 15, 2025
Q4 20241.29%10,000,000SEC filing ↗Filed Feb 27, 2025Amended
Q3 20240.82%7,000,000SEC filing ↗Filed Nov 14, 2024
Q2 20240.99%10,000,000SEC filing ↗Filed Aug 14, 2024
Q1 20240.50%4,500,000SEC filing ↗Filed May 14, 2024
Q4 20230.63%5,000,000SEC filing ↗Filed Feb 13, 2024
Q3 20230.51%5,000,000SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20230.51%5,000,000$3.75MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 20230.63%5,000,000$4.22MPrincipal unchanged; reported value increased 12.39%, and weight changed +0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2024
Q1 20240.50%4,500,000$3.71MPrincipal decreased 10.00%; reported value decreased 12.05%, and weight changed -0.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2024
Q2 20240.99%10,000,000$8.08MPrincipal increased 122.22%; reported value increased 117.83%, and weight changed +0.49 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20240.82%7,000,000$5.85MPrincipal decreased 30.00%; reported value decreased 27.52%, and weight changed -0.17 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20241.29%10,000,000$8.54MPrincipal increased 42.86%; reported value increased 45.95%, and weight changed +0.47 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 27, 2025
Q1 20251.31%9,000,000$8.10MPrincipal decreased 10.00%; reported value decreased 5.19%, and weight changed +0.02 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20251.87%13,000,000$12.17MPrincipal increased 44.44%; reported value increased 50.27%, and weight changed +0.56 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2025
Q3 20251.21%9,450,000$9.35MPrincipal decreased 27.31%; reported value decreased 23.18%, and weight changed -0.66 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2025
Q4 20254.54%26,950,000$30.35MPrincipal increased 185.19%; reported value increased 224.63%, and weight changed +3.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20264.88%22,032,000$24.76MPrincipal decreased 18.25%; reported value decreased 18.43%, and weight changed +0.34 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 21, 2026
Q2 20262.75%19,532,000$21.73MPrincipal decreased 11.35%; reported value decreased 12.24%, and weight changed -2.13 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2026
SILVERBACK ASSET MANAGEMENT LLC · BRIDGEBIO PHARMA INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1278960","quarter":"2026Q2","cusip":"10806XAD4"}

get_institutional_manager_history
{"cik":"1278960","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.